2026 · 2nd Quarter (Apr 1 - June 30)
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Literal source text
Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.
Literal federal measure citations: H.R. 1
Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.
Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.
Issues related to pharmaceutical tariffs and related trade agreements.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
